Lacosamide Teva (Lacosamide)

Lacosamide is an anticonvulsant that acts on focal seizure activity.

• Partial‑onset seizures: reduces seizure frequency as adjunct therapy.
• Focal seizures with secondary generalization: helps control spread of seizure activity.
• Epilepsy (adjunctive): contributes to overall seizure management when combined with other antiepileptic drugs.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing neuronal membranes and limiting repetitive firing. It also binds to collapsin response mediator protein‑2 (CRMP‑2), which may modulate neuronal differentiation and axonal outgrowth, contributing to its antiepileptic effect.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Nausea: feeling of stomach upset or urge to vomit.
• Fatigue: unusual tiredness or lack of energy.
• Headache: mild to moderate head pain.
• Blurred vision: temporary visual disturbances.
• Diplopia: double vision.

Serious or Rare Side Effects

• Suicidal thoughts: emergence of depressive or suicidal ideation.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Cardiac arrhythmia: abnormal heart rhythm, especially PR‑interval prolongation.
• Respiratory depression: reduced breathing effort.
• Hypersensitivity reactions: rash, swelling, or anaphylaxis.
• Elevated liver enzymes: signs of hepatic stress.

Before prescribing Lacosamide, clinicians should consider several safety factors.

• Renal impairment: adjust dose or monitor renal function.
• Hepatic impairment: evaluate liver function and consider dose modification.
• Cardiac conduction disorders: monitor ECG for PR‑interval changes.
• Concomitant antiepileptics: assess for additive CNS depression.
• Pregnancy safety: limited data; weigh potential benefits against risks.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Lacosamide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin): may reduce lacosamide levels.
• Other sodium‑channel blockers (e.g., carbamazepine): increase risk of cardiac conduction effects.
• Concomitant use with QT‑prolonging agents: may exacerbate cardiac rhythm disturbances.

Moderate Interactions (Monitor Closely):\n- CYP2C19 inhibitors (e.g., fluoxetine, omeprazole): may raise lacosamide concentrations.

• Alcohol: can enhance CNS depression and dizziness.
• Additional antiepileptic drugs (e.g., valproate): monitor for additive side effects.